Osimertinib for the treatment of non-small cell lung cancer.

about

Osimertinib for the treatment of non-small cell lung cancer.

Item

http://www.wikidata.org/entity/Q39002726

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Osimertinib for the treatment of non-small cell lung cancer.

@en

Osimertinib for the treatment of non-small cell lung cancer.

@nl

type

Item

label

Osimertinib for the treatment of non-small cell lung cancer.

@en

Osimertinib for the treatment of non-small cell lung cancer.

@nl

prefLabel

Osimertinib for the treatment of non-small cell lung cancer.

@en

Osimertinib for the treatment of non-small cell lung cancer.

@nl

P1476

Osimertinib for the treatment of non-small cell lung cancer.

@en

P2093

Jin Seok Ahn

http://www.w3.org/2001/XMLSchema#string

Jong-Mu Sun

http://www.w3.org/2001/XMLSchema#string

Keunchil Park

http://www.w3.org/2001/XMLSchema#string

Myung-Ju Ahn

http://www.w3.org/2001/XMLSchema#string

Se-Hoon Lee

http://www.w3.org/2001/XMLSchema#string

P2860

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

Rociletinib in EGFR-mutated non-small-cell lung cancer.

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.

P304

225-231

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14656566.2017.1285283

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-01-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28116908

http://www.w3.org/2001/XMLSchema#string